Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Lenalidomide
gptkb:ARCH_trial gptkb:Kyprolis |
| gptkbp:activities |
proteasome inhibitor
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:can_be_used_with |
gptkb:bortezomib
gptkb:lenalidomide gptkb:dexamethasone |
| gptkbp:clinical_trial |
Phase 2
ENDEAVOR trial ASPIRE trial FUSION trial |
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to carfilzomib |
| gptkbp:developed_by |
gptkb:Onyx_Pharmaceuticals
|
| gptkbp:effective_date |
gptkb:2012
|
| gptkbp:financial_performance |
reconstituted solution stable for 24 hours at room temperature
|
| https://www.w3.org/2000/01/rdf-schema#label |
carfilzomib
|
| gptkbp:indication |
gptkb:refractory_multiple_myeloma
relapsed multiple myeloma |
| gptkbp:ingredients |
C22 H30 N4 O5 S
|
| gptkbp:interacts_with |
anticoagulants
live vaccines CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 X X32
|
| gptkbp:is_available_on |
lyophilized powder
|
| gptkbp:is_monitored_by |
cardiac function
renal function blood counts |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:manager |
intravenous
|
| gptkbp:pharmacokinetics |
metabolized by liver
inhibits proteasome activity elimination half-life of 15 minutes |
| gptkbp:population |
adults
|
| gptkbp:provides_information_on |
oncology
hematology |
| gptkbp:research_focus |
biomarker identification
combination therapies long-term outcomes resistance mechanisms |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea diarrhea thrombocytopenia infection risk neuropathy hyperglycemia pulmonary toxicity cardiac toxicity |
| gptkbp:storage |
store at 2-8° C
|
| gptkbp:traded_on |
gptkb:Kyprolis
|
| gptkbp:type_of |
868540-17-4
|
| gptkbp:weight |
450.56 g/mol
|